title: Serial changes of lung morphology and biochemical profiles in a rat model of bronchopulmonary dysplasia induced by intra-amniotic lipopolysaccharide and postnatal hyperoxia.
abstract: to investigate serial changes of lung morphology and biochemical profiles in a rat model of bronchopulmonary dysplasia (BPD) induced by intra-amniotic lipopolysaccharide (LPS) administration and postnatal hyperoxia (85%).
  
  
  
  we evaluated histological changes of the lungs and compared the levels of interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), and protein carbonyl in lung tissue on days 1, 7, and 14 after birth in a rat model of BPD.
  
  
  
  the inhibition of alveolarization was sustained in the LPS plus hyperoxia group from day 7 to 14, whereas alveolarization resumed in the hyperoxia group after oxygen exposure was withdrawn at day 7. Administration of LPS alone did not adversely affect lung morphometry. IL-6 levels showed transient overexpression at day 1 in the LPS-treated groups, but decreased at days 7 and 14. VEGF protein levels were elevated in the LPS-treated groups, but not in the hyper-oxia and control groups at days 1, 7, and 14. Exposure to hyperoxia affected protein carbonyl levels in the hyperoxia group at days 7 and 14.
  
  
  
  lung injury induced by intra-amniotic inflammation and postnatal hyperoxia may be due to inhibition of alveolarization without recovery even after withdrawal of oxygen.
authors: Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
authors: Hyun Ju
authors: HJ
authors: Lee
authors: Chang Won
authors: CW
authors: Choi
authors: Beyong Il
authors: BI
authors: Kim
authors: Ee-Kyung
authors: EK
authors: Kim
authors: Han-Suk
authors: HS
authors: Kim
authors: Jung-Hwan
authors: JH
authors: Choi
authors: Myong Jin
authors: MJ
authors: Lee
authors: Eun Gyeong
authors: EG
authors: Yang
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001997:Bronchopulmonary Dysplasia / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology*; D004195:Disease Models, Animal; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D018496:Hyperoxia / Q000473:pathology; D007231:Infant, Newborn; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D011247:Pregnancy; D050050:Protein Carbonylation; D011650:Pulmonary Alveoli / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D051381:Rats; D017207:Rats, Sprague-Dawley; D016019:Survival Analysis; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D015850:Interleukin-6; D008070:Lipopolysaccharides; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A